Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism

Osteonecrosis of femoral head (ONFH) is a progressive hip joint disease without disease-modifying treatment. Lacking understanding of the pathophysiological process of ONFH has become the humper to develop therapeutic approach. Serum amyloid A (SAA) is an acute phase lipophilic protein during inflam...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyuan Peng (Author), Yiyang Ma (Author), Qiyang Wang (Author), Yanchun Gao (Author), Guangyi Li (Author), Chenyi Jiang (Author), Yun Gao (Author), Yong Feng (Author)
Format: Book
Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e096603b51de4d9d84f80048b7221338
042 |a dc 
100 1 0 |a Xiaoyuan Peng  |e author 
700 1 0 |a Yiyang Ma  |e author 
700 1 0 |a Qiyang Wang  |e author 
700 1 0 |a Yanchun Gao  |e author 
700 1 0 |a Guangyi Li  |e author 
700 1 0 |a Chenyi Jiang  |e author 
700 1 0 |a Yun Gao  |e author 
700 1 0 |a Yong Feng  |e author 
245 0 0 |a Serum Amyloid A Correlates With the Osteonecrosis of Femoral Head by Affecting Bone Metabolism 
260 |b Frontiers Media S.A.,   |c 2021-10-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2021.767243 
520 |a Osteonecrosis of femoral head (ONFH) is a progressive hip joint disease without disease-modifying treatment. Lacking understanding of the pathophysiological process of ONFH has become the humper to develop therapeutic approach. Serum amyloid A (SAA) is an acute phase lipophilic protein during inflammation and we found that SAA is increased for the first time in the serum of ONFH patients through proteomic studies and quantitatively verified by ELISA. Treating rBMSCs with SAA inhibited the osteogenic differentiation via Wnt/β-catenin signaling pathway deactivation and enhanced the adipogenic differentiation via MAPK/PPARγ signaling pathway activation. Finally, bilateral critical-sized calvarial-defect rat model which received SAA treated rBMSCs demonstrated reduction of bone formation when compared to untreated rBMSCs implantation control. Hence, SAA is a vital protein in the physiological process of ONFH and can act as a potential therapeutic target to treat ONFH. 
546 |a EN 
690 |a serum amyloid a 
690 |a osteonecrosis of femoral head 
690 |a proteomics 
690 |a wnt/β-catenin signaling pathway 
690 |a MAPK/PPARγ signaling pathway 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 12 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2021.767243/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/e096603b51de4d9d84f80048b7221338  |z Connect to this object online.